What type of study is this?

December 8, 2025Blood

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

TFTracelyn FreemanThe Ohio State University MWMichael J. WalkerUniversity of Southern California NGNicole R. GrieselhuberThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Discussion

Member takes

Implication

Retrospective analysis reports equal efficacy and differences in toxicity for cytarabine dosing in older adults with acute myeloid leukemia, suggesting careful consideration for treatment.

Key Points

Overall survival and disease-free survival did not significantly differ between cytarabine consolidation doses in older adults.
Toxicity events were prevalent, with febrile neutropenia occurring in 69% of patients receiving intermediate dose cytarabine.
Single center retrospective analysis examined outcomes for older adults diagnosed with acute myeloid leukemia and cytarabine treatment.
Implications for treatment approaches highlight the need for further research in dosing strategies for older patients.

Cite This Study

Freeman et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da5b https://doi.org/10.1182/blood-2025-3408

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reports equal efficacy and differences in toxicity for cytarabine dosing in older adults with acute myeloid leukemia, suggesting careful consideration for treatment.